250+ Clinical Trials: Hosted at Alpha Clinics for CIRM funded and other research. 2000+ Patients Enrolled: Pioneers who participated in a clinical trial at an Alpha Clinic. 40+ Diseases & Conditions: ...

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus ...

CIRM is supporting a network of 11 Shared Resources Laboratories (SRLs) for Stem Cell-Based Modeling, an important component of CIRM’s Infrastructure Program designed to address challenges that hinder ...

The California Cell and Gene Therapy Manufacturing Network was established by CIRM to expand the manufacturing capabilities necessary to bring stem cell and gene therapies from foundational research ...

CIRM Disclaimer: The information in the table has been collected by CIRM to help CIRM awardees accelerate the development of pluripotent stem cell-derived therapeutics. The information is intended to ...

About the California Institute for Regenerative Medicine (CIRM) At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet ...

FOR IMMEDIATE RELEASE Contact: Esteban Cortez Director, Marketing & Communications [email protected] South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine ...

About the California Institute for Regenerative Medicine (CIRM) At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet ...

About the California Institute for Regenerative Medicine (CIRM) At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet ...

FOR IMMEDIATE RELEASE Contact: Koren Temple-Perry Sr. Director, Marketing & Communications [email protected] South San Francisco, CA, November 21, 2024 – The California Institute for Regenerative ...

Through the $4.7 million award, Aaron Nagiel, MD, PhD, and the team at Blue Gen Therapeutics Foundation will advance the development of a novel gene therapy for BCM, a rare, inherited eye disease that ...

Vito Imbasciani, PhD, MD, and Jonathan Thomas, PhD, JD FOR IMMEDIATE RELEASE Contact: Koren Temple-Perry Sr. Director, Marketing & Communications [email protected] South San Francisco, CA, Dec. 15, ...